Clinical Trials
4
Active:4
Completed:0
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: ARV-471 in combination with Everolimus
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Arvinas Estrogen Receptor, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05501769
- Locations
- 🇪🇸
Clinical Trial Site, Valencia, Spain
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: ARV-471 in combination with palbociclib (IBRANCE®)
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Arvinas Estrogen Receptor, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT04072952
- Locations
- 🇺🇸
Clinical Trial Site, Seattle, Washington, United States
News
No news found